文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Combined PARP and Immune Checkpoint Inhibition in Ovarian Cancer.

作者信息

Lee Elizabeth K, Konstantinopoulos Panagiotis A

机构信息

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

出版信息

Trends Cancer. 2019 Sep;5(9):524-528. doi: 10.1016/j.trecan.2019.06.004. Epub 2019 Jul 15.

DOI:10.1016/j.trecan.2019.06.004
PMID:31474356
Abstract

Recent studies have demonstrated that, besides direct cytotoxic effects, poly(ADP ribose) polymerase (PARP) inhibitors (PARPis) exhibit antitumor immunity that occurs in a stimulator of interferon genes (STING)-dependent manner and is augmented by immune checkpoint blockade (CPB). In ovarian cancer, combined PARP and immune checkpoint inhibition has yielded encouraging preliminary results in two early-phase clinical trials and is currently being evaluated in both first-line and recurrent settings.

摘要

相似文献

[1]
Combined PARP and Immune Checkpoint Inhibition in Ovarian Cancer.

Trends Cancer. 2019-9

[2]
PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness.

Cancer Res. 2018-11-27

[3]
Do increased tumor infiltrating lymphocytes co-existing with Homologous Recombination Deficiency provide clues to enhance immunotherapy of ovarian cancer?

Gynecol Oncol. 2019-5

[4]
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer.

Nat Commun. 2020-3-19

[5]
PARP (Poly(ADP-Ribose) Polymerase) Inhibitors in Platinum-Sensitive Recurrent Ovarian Cancer: A Meta-Analysis of Randomized Controlled Trials.

Oncol Res Treat. 2018

[6]
PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer.

Cell Rep. 2018-12-11

[7]
NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer.

Nat Commun. 2020-4-3

[8]
PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.

Cancer. 2018-4-16

[9]
Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion.

Cancer Lett. 2019-10-9

[10]
Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer.

Breast Cancer Res Treat. 2023-1

引用本文的文献

[1]
Latest Advancements of Natural Products in Combating Ovarian Cancer.

J Cancer. 2025-7-28

[2]
Advances and obstacles of T cell-based immunotherapy in gynecological malignancies.

Mol Cancer. 2025-7-26

[3]
Identification of parthanatos-related molecular subtypes and development of prognostic risk models in ovarian cancer based on multi-omics analysis.

J Ovarian Res. 2025-7-2

[4]
Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer: Japan subset from the phase III DUO-E trial.

J Gynecol Oncol. 2025-7

[5]
Elucidating DNA Damage-Dependent Immune System Activation.

Int J Mol Sci. 2025-6-18

[6]
Unlocking the potential of immunotherapy in platinum-resistant ovarian cancer: rationale, challenges, and novel strategies.

Cancer Drug Resist. 2024-10-15

[7]
Advanced endometrial cancer-The next generation of treatment: A society of gynecologic oncology journal club clinical commentary.

Gynecol Oncol Rep. 2024-7-18

[8]
Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy.

J Transl Med. 2024-8-9

[9]
A Comprehensive Analysis Exploring the Impact of an Immunogenic Cell Death-Related Panel for Ovarian Cancer.

Mol Biotechnol. 2025-6

[10]
Targeting ATR Pathway in Solid Tumors: Evidence of Improving Therapeutic Outcomes.

Int J Mol Sci. 2024-2-27

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索